Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

HANGZHOU, China, June 14, 2024 /PRNewswire/ — Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that its in-house developed innovative transcatheter pulmonic valve replacement (TPVR)…